Jesús Oliva1, Mercedes Díez2, Silvia Galindo3, Carlos Cevallos4, Ana Izquierdo5, Javier Cereijo6, Arantxa Arrillaga7, Antonio Nicolau8, Ana Fernández9, Mara Alvarez10, Jesús Castilla11, Eva Martínez12, Irene López13, Nuria Vivés14. 1. Plan Nacional sobre el Sida/Centro Nacional de Epidemiología, Unidad de Epidemiología del VIH/SIDA y Conductas de Riesgo, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: jaoliva@isciii.es. 2. Plan Nacional sobre el Sida/Centro Nacional de Epidemiología, Unidad de Epidemiología del VIH/SIDA y Conductas de Riesgo, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Spain. 3. Plan Nacional sobre el Sida/Centro Nacional de Epidemiología, Unidad de Epidemiología del VIH/SIDA y Conductas de Riesgo, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain. 4. Servicio de Epidemiología, Subdirección de Promoción de la Salud y Prevención, Consejería de Sanidad, Comunidad de Madrid, Spain. 5. Servicio de Epidemiología y Prevención, Dirección General de Salud Pública, Servicio Canario de la Salud, Sta. Cruz de Tenerife, Spain. 6. Servizo de Control de Enfermidades Transmisibles, Dirección Xeral de Innovación e Xestión da Saúde Pública, Xunta de Galicia, Spain. 7. Plan de Prevención y Control del Sida del País Vasco, San Sebastián, Spain. 8. Servicio de Epidemiología, Dirección General de Salud Pública, Consejería de Salud y Consumo del Gobierno Balear, Palma de Mallorca, Spain. 9. Servicio de Vigilancia y Alertas Epidemiológicas, Dirección General Salud Pública y Participación, Consejería de Salud y Servicios Sanitarios del Principado de Asturias, Oviedo, Spain. 10. Subdirección de Epidemiología, Servicio Extremeño de Salud, Junta de Extremadura, Mérida, Spain. 11. Instituto de Salud Pública de Navarra, Pamplona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Spain. 12. Servicio de Epidemiología y Prevención Sanitaria, Consejería de Salud del Gobierno de La Rioja, Logroño, Spain. 13. Servicio de Epidemiología, Consejería de Sanidad y Consumo de la Ciudad Autónoma de Ceuta, Spain. 14. Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Institut Català d'Oncologia (ICO), Direcció General de Salut Pública, Generalitat de Catalunya, Badalona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Spain.
Abstract
OBJECTIVE: To present surveillance data on advanced disease (AD) and late presentation (LP) of HIV in Spain and their determinants. METHODS: We included all new HIV diagnoses notified by the autonomous regions that consistently reported such cases throughout the period 2007-2011. Coverage was 54% of the total Spanish population. Data sources consisted of clinicians, laboratories and medical records. AD was defined as the presence of a CD4 cell count <200cells/μL in the first test after HIV diagnosis, while LP was defined as the presence of a CD4 cell count <350cells/μL after HIV diagnosis. Odds ratios and their 95% confidence intervals (OR, 95% CI) were used as the measure of association. Logistic regressions were fit to identify predictors of AD and LP. RESULTS: A total of 13,021 new HIV diagnoses were included. Among these, data on the outcome variable were available in 87.7%. The median CD4 count at presentation was 363 (interquartile range, 161-565). Overall, 3356 (29.4%) patients met the definition of AD and 5494 (48.1%) were classified as LP. Both AD and LP increased with age and were associated with male sex and infection through drug use or heterosexual contact. All immigrants except western Europeans were more prone to AD and LP. Multivariate models disaggregated by sex showed that the effect of age and region of origin was weaker in women than in men. CONCLUSIONS: Despite universal health care coverage in Spain, men, immigrants and people infected through drug use or heterosexual contact seem to be experiencing difficulties in gaining timely access to HIV care.
OBJECTIVE: To present surveillance data on advanced disease (AD) and late presentation (LP) of HIV in Spain and their determinants. METHODS: We included all new HIV diagnoses notified by the autonomous regions that consistently reported such cases throughout the period 2007-2011. Coverage was 54% of the total Spanish population. Data sources consisted of clinicians, laboratories and medical records. AD was defined as the presence of a CD4 cell count <200cells/μL in the first test after HIV diagnosis, while LP was defined as the presence of a CD4 cell count <350cells/μL after HIV diagnosis. Odds ratios and their 95% confidence intervals (OR, 95% CI) were used as the measure of association. Logistic regressions were fit to identify predictors of AD and LP. RESULTS: A total of 13,021 new HIV diagnoses were included. Among these, data on the outcome variable were available in 87.7%. The median CD4 count at presentation was 363 (interquartile range, 161-565). Overall, 3356 (29.4%) patients met the definition of AD and 5494 (48.1%) were classified as LP. Both AD and LP increased with age and were associated with male sex and infection through drug use or heterosexual contact. All immigrants except western Europeans were more prone to AD and LP. Multivariate models disaggregated by sex showed that the effect of age and region of origin was weaker in women than in men. CONCLUSIONS: Despite universal health care coverage in Spain, men, immigrants and people infected through drug use or heterosexual contact seem to be experiencing difficulties in gaining timely access to HIV care.
Authors: Donna M Tilley; Elizabeth Griggs; Jennifer Hoy; Stephen T Wright; Ian Woolley; Michael Burke; Catherine C O'Connor Journal: AIDS Care Date: 2015
Authors: J Reyes-Urueña; C Campbell; C Hernando; N Vives; C Folch; L Ferrer; L Fernández-López; A Esteve; J Casabona Journal: Epidemiol Infect Date: 2017-03-08 Impact factor: 4.434
Authors: Alejandro Alvaro-Meca; Ines Palomares-Sancho; Asuncion Diaz; Rosa Resino; Angel Gil De Miguel; Salvador Resino Journal: J Int AIDS Soc Date: 2015-05-20 Impact factor: 5.396
Authors: Alvaro Mena; Luz Moldes; Héctor Meijide; Angelina Cañizares; Angeles Castro-Iglesias; Manuel Delgado; Sonia Pértega; José Pedreira; Germán Bou; Eva Poveda Journal: PLoS One Date: 2014-12-01 Impact factor: 3.240
Authors: Alejandro Álvaro-Meca; Asuncion Díaz; Javier de Miguel Díez; Rosa Resino; Salvador Resino Journal: PLoS One Date: 2016-11-03 Impact factor: 3.240